1. Home
  2. ASMB vs EARN Comparison

ASMB vs EARN Comparison

Compare ASMB & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • EARN
  • Stock Information
  • Founded
  • ASMB 2005
  • EARN 2012
  • Country
  • ASMB United States
  • EARN United States
  • Employees
  • ASMB N/A
  • EARN N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • EARN Real Estate Investment Trusts
  • Sector
  • ASMB Health Care
  • EARN Real Estate
  • Exchange
  • ASMB Nasdaq
  • EARN Nasdaq
  • Market Cap
  • ASMB 198.6M
  • EARN 223.5M
  • IPO Year
  • ASMB 2010
  • EARN 2013
  • Fundamental
  • Price
  • ASMB $21.85
  • EARN $5.64
  • Analyst Decision
  • ASMB Strong Buy
  • EARN Buy
  • Analyst Count
  • ASMB 4
  • EARN 2
  • Target Price
  • ASMB $41.33
  • EARN $6.13
  • AVG Volume (30 Days)
  • ASMB 148.4K
  • EARN 301.3K
  • Earning Date
  • ASMB 11-06-2025
  • EARN 11-11-2025
  • Dividend Yield
  • ASMB N/A
  • EARN 17.02%
  • EPS Growth
  • ASMB N/A
  • EARN N/A
  • EPS
  • ASMB N/A
  • EARN N/A
  • Revenue
  • ASMB $33,247,000.00
  • EARN $35,893,000.00
  • Revenue This Year
  • ASMB $12.44
  • EARN N/A
  • Revenue Next Year
  • ASMB N/A
  • EARN $15.96
  • P/E Ratio
  • ASMB N/A
  • EARN N/A
  • Revenue Growth
  • ASMB 54.77
  • EARN 43.30
  • 52 Week Low
  • ASMB $7.75
  • EARN $4.33
  • 52 Week High
  • ASMB $27.17
  • EARN $7.11
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.57
  • EARN 43.69
  • Support Level
  • ASMB $22.36
  • EARN $5.56
  • Resistance Level
  • ASMB $23.61
  • EARN $5.70
  • Average True Range (ATR)
  • ASMB 1.30
  • EARN 0.08
  • MACD
  • ASMB -0.60
  • EARN -0.01
  • Stochastic Oscillator
  • ASMB 3.37
  • EARN 24.85

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: